Navigation Links
Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
Date:7/27/2009

FREMONT, Calif., July 27 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced data suggesting that QPI-1007 prevents progressive retinal ganglion cell (RGC) loss in an increased ocular pressure (IOP) rat model of glaucoma. The experiments performed by Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Universite de Montreal, indicate that QPI-1007 has the potential to treat patients with glaucoma. QPI-1007 is being evaluated in advanced IND-enabling preclinical studies as a neuroprotective agent for eye diseases.

QPI-1007 is Quark's first proprietary siRNA drug candidate developed in collaboration with BioSpring GmbH, with its own intellectual property that gives Quark freedom to operate in the siRNA IP space. Previously announced studies have demonstrated a robust neuroprotective effect of QPI-1007 in two additional models of retinal ganglion cell (RGC) death - induced by optic nerve crush or axotomy. In those studies, QPI-1007 was administered immediately after the optic nerve injury. In the current IOP study, QPI-1007 was administered 2 weeks after disease induction when more than 25% of RGCs have already been lost. Whereas RGC loss progressed in the control eyes, loss of RGCs was completely blocked in the QPI-1007-treated eyes

Dr. Daniel Zurr, Quark's Chief Executive Officer, stated, "Quark is pleased to announce additional data supporting the therapeutic potential of QPI-1007 -- the first siRNA drug candidate based on our own IP -- as well as our proven ability to advance siRNA products from discovery to the clinic. Our leadership position within the RNAi field is set to continue with the upcoming IND filing for QPI-1007 to support initial clinical studies in non-arteritic anterior ischemic optic neuropathy. Quark has the largest portfolio of clinical-stage s
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
2. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
3. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
4. Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... surprising new study pulls back the curtain on one ... in payment and income between physicians who perform operations, ... Contrary to perception, the research indicates, the physician payment ... other procedure-performing doctors. , The new findings counter the ... per minute explains why doctors who perform procedures often ...
(Date:9/22/2014)... Norton HealthDay Reporter MONDAY, ... better when newborn intensive care units (NICU) set up private ... new study finds. Researchers at one children,s hospital found ... less distressed when their NICU switched from the traditional "open-bay" ... online Sept. 22 in the journal Pediatrics , add ...
(Date:9/22/2014)... of patients undergoing breast cancer surgery require additional operations ... tissue in the initial operation. However, researchers at Brigham ... they developed that will help surgeons better distinguish cancerous ... for repeat operations. , The study ... in the Proceedings of the National Academy of ...
(Date:9/22/2014)... (September 22, 2014) McMaster scientists have found that ... class of antibiotics. , Although dozens of antibiotics ... how a certain part of bacteria are created, and ... , The discovery is important as there is ... the cures for infections ineffective. The World Health Organization ...
(Date:9/22/2014)... This Flash Report is a top-line view ... the Prostate Cancer market. , Download the flash report ... any launching Prostate Cancer product:, ... crowded market , Understanding stakeholder interactions with ... thought leaders and stakeholders ,Download the white paper ...
Breaking Medicine News(10 mins):Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:The fine line between breast cancer and normal tissues 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2
... engineer has developed a technique which uses plastidial transformation ... (HSA) from tobacco plants. HSA is an intravenous protein ... ,It is mainly used to stabilize blood ... is used for haemorrhages, burns, surgical operations or when ...
... Veterinary schools in sub-Saharan Africa have joined forces ... allow vets to study// for postgraduate degrees while ... Veterinary E-Learning Consortium, launched in early March, will ... full-time degrees, reported the SciDev.net science-for-development network. ...
... Conference (EBCC-5) have called that patients should have speedy access ... Doctors and patient groups said that women in Europe are ... could help prolong their survival and well being. ... are available to women in the United States far more ...
... Quest? cigarettes seems to have lulled smokers into a ... by researchers// at the Transdisciplinary Tobacco Use Research Center ... the study have been published in the journal Psychology ... study, Caryn Lerman, PhD, Associate Director for Cancer Control ...
... revealed that Africa's TB crisis has its origin in HIV/AIDS, ... two million people who die from TB every year, 1.5 ... the African Medical and Research Foundation (AMREF) clinic in the ... to TB were also infected with HIV. According to Nzioka, ...
... According to studies done at the Yale school of medicine, ... we get when we eat certain foodstuffs//, like garlic, mustard ... receptor they ay also underlines the reaction of the body ... vehicle exhaust and byproducts of certain chemo receptor drugs used ...
Cached Medicine News:Health News:Alternate ways to produce HAS from tobacco plants 2
(Date:9/22/2014)... Mass. , Sept. 22, 2014  Seres Health, ... related to the human microbiome, today announced that it ... of 2014,s Fierce 15 biotechnology companies, designating it as ... the industry.  "Amid a great deal ... for its focus and commitment to practical therapeutic development," ...
(Date:9/22/2014)... PLEASANTON, Calif. , Sept. 22, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... D. Keith Grossman has been appointed President and ... F. Burbach , who has stepped down from his ... advisor to the company through the first quarter of ...
(Date:9/22/2014)... cancer is the second leading cause of cancer death ... early - the problem is that too often it ... Education Council (PCEC), – a national organization committed ... screening –  is sponsoring its 25 th Annual ... Committed to encouraging men to take a ...
Breaking Medicine Technology:Seres Health Named a "Fierce 15" Biotech Company for 2014 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 4Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 5PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 2PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 3
... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... of the largest network of radiotherapy and diagnostic imaging ... directors approved a share repurchase program, effective immediately. ... States federal securities laws, Concord Medical is authorized to ...
... Sept. 29, 2011 The Educational Review System held ... 28 at the Meyedenbauer Center in Bellevue, WA. Attendees ... pharmacy thought leaders discuss the challenges of pediatric medications, ... the 2010 recipient of the Institute for Safe Medication ...
Cached Medicine Technology:Concord Medical Services Announces Share Repurchase Program 2Concord Medical Services Announces Share Repurchase Program 3
For injecting viscoelastic to all meridians of the anterior chamber and to coat intraocular lenses. 20G x 7.8in (.90 x 22mm)....
For administering anesthetic agents into the posterior sub-Tenon's space 20G x 1in (.90 x 25mm)...
... is the most versatile diagnostic tool in ... solutions for glaucoma, diabetic retinopathy, age-related macular ... RTA is the only system in the ... pole and the optic nerve areas in ...
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Medicine Products: